Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Pertussis

Pertussis

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Pertussis

62 trials tracked for Pertussis: 44 in phase 3 or 4 and 7 with published results. The most-cited published study has 37 citations.

62Trials tracked
44Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 15 Phase 3 29 Phase 2 7 Phase 1 5 Other / NA 6
  1. Phase 4 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed · 37 cited
  2. Phase 3 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed · 13 cited
  3. Phase 3 Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012) Completed · 9 cited
  4. Phase 3 A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Completed · 6 cited
  5. Phase 4 Study of Adacel® Vaccine Administered to Persons 10 Years of Age Completed · 5 cited
  6. Phase 4 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed · 5 cited
Show 44 more trials
  1. Phase 3 Confirmatory Study of BK1310 in Healthy Infants Completed · 1 cited
  2. Phase 4 Post Marketing Surveillance for ADACEL™ in South Korea Completed
  3. Phase 4 Tdap Vaccine in Post-Partum Women Completed
  4. Phase 4 Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX® Completed
  5. Phase 4 A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older Completed
  6. Phase 4 Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination Completed
  7. Phase 4 Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine Completed
  8. Phase 4 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed
  9. Phase 4 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed
  10. Phase 4 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed
  11. Phase 4 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed
  12. Phase 4 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed
  13. Phase 4 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed
  14. Phase 3 Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents Completed
  15. Phase 3 Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants Completed
  16. Phase 3 Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants Completed
  17. Phase 3 Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B Completed
  18. Phase 3 Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants Completed
  19. Phase 3 Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV Completed
  20. Phase 3 Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants Completed
  21. Phase 3 Immunogenicity and Safety of Adacel Polio Vaccine Completed
  22. Phase 3 A Study to Assess the Safety of Adacel® Vaccine Completed
  23. Phase 3 Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan Completed
  24. Phase 3 Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age Completed
  25. Phase 3 Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ Completed
  26. Phase 3 Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age Completed
  27. Phase 3 Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule Completed
  28. Phase 3 Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine Completed
  29. Phase 3 Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. Completed
  30. Phase 3 A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents Completed
  31. Phase 3 Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL® Completed
  32. Phase 3 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants Completed
  33. Phase 3 Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Completed
  34. Phase 3 Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old Completed
  35. Phase 3 Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ Completed
  36. Phase 3 Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants Completed
  37. Phase 3 Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants Completed
  38. Phase 3 Safety and Immune Response of Different Pediatric Combination Vaccines. Completed
  39. Phase 2 Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults Completed
  40. Phase 2 Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults Completed
  41. Phase 2 Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects Completed
  42. Phase 2 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants Completed
  43. Phase 2 Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants Completed
  44. Phase 2 Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® Completed

Showing the 50 most-cited and recently-updated of 62 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Serological surveillance reveals 23.3% global pooled pertussis seropositivity and 3.6% recent infection rate across 37 countries
Primary Care & Family Medicine Meta-analysis
Serological surveillance reveals 23.3% global pooled pertussis seropositivity and 3.6% recent infection rate across 37 countries Pertussis infection rates vary widely by age and region in a global review
This systematic review and meta-analysis evaluated serological surveillance data from approximately 87,000 participants in 37 countries. The…
A global review of 87,000 people found that recent whooping cough infection rates differ significantly by age group and geographic location.
Frontiers Jun 3, 2026
Pregnant women unvaccinated against pertussis had infants with higher anti-PT IgG levels at six months
Pediatrics
Pregnant women unvaccinated against pertussis had infants with higher anti-PT IgG levels at six months Unvaccinated mothers pass stronger pertussis antibodies to babies than vaccines do
This prospective open-label controlled clinical trial evaluated the effect of immunization during pregnancy on anti-pertussis toxin antibodi…
Antibodies against whooping cough passed from unvaccinated mothers to babies were stronger than those from vaccinated mothers, challenging c…
Apr 30, 2026
ACIP updates adult vaccination recommendations, allowing Tdap or Td in more scenarios
Allergy & Immunology
ACIP updates adult vaccination recommendations, allowing Tdap or Td in more scenarios New vaccine rules give adults more options for tetanus and whooping cough protection
The Advisory Committee on Immunization Practices has updated recommendations for adult vaccination in the United States.
Adults in the U.S. now have more options for their tetanus shots, as health advisors say both Tdap and Td vaccines are acceptable for routin…
CDC Apr 4, 2026
Influenza and pertussis cause substantial disease burden in pregnant women and unvaccinated infants
OB/GYN & Women's Health
Influenza and pertussis cause substantial disease burden in pregnant women and unvaccinated infants Influenza and pertussis pose significant health risks to pregnant women and young infants
A review of evidence from the United States describes the disease burden of influenza and pertussis among pregnant women and infants too you…
Flu and whooping cough cause serious sickness in pregnant women and infants too young for vaccines, making protection a top public health pr…
CDC Apr 4, 2026
New 6-in-1 infant vaccine licensed but availability delayed until at least 2021
Gastroenterology
New 6-in-1 infant vaccine licensed but availability delayed until at least 2021 New six-in-one vaccine for infants receives regulatory approval
A new combination vaccine for infants targeting diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B has received licensure.
A new six-in-one vaccine for infants has received regulatory approval, but it won't be available for use until 2021 or later.
CDC Apr 3, 2026
Meta-Analysis IDs Top 5 Factors for Severe Pertussis in Chinese Children, Including Lung Consolidation (OR 15.44)
Pediatrics Meta-analysis
Meta-Analysis IDs Top 5 Factors for Severe Pertussis in Chinese Children, Including Lung Consolidation (OR 15.44) What puts a child at highest risk for severe whooping cough? A new analysis of Chinese children reveals the top five warning signs
A meta-analysis of 24 studies including 839 severe and 4,280 non-severe pertussis cases in Chinese children identified the strongest factors…
Lung complications and lack of vaccination are the top five warning signs that put a child at highest risk for severe whooping cough.
Mar 30, 2026

Questions about Pertussis

Can pregnant women who are unvaccinated against Pertussis still pass antibodies to their babies?

Yes, unvaccinated pregnant women pass antibodies to their babies, and research shows these infants often have higher antibody levels at six months compared to those born to vaccinated mothers.

Full answer →
Does getting a Tdap shot as an adult help prevent Pertussis in infants?

Getting a Tdap shot during pregnancy helps protect infants by passing antibodies to them, but it does not directly vaccinate the baby. Unvaccinated infants face higher risks of severe disease.

Full answer →